Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 22957013)

1.

Short-term erythropoietin treatment does not substantially modulate monocyte transcriptomes of patients with combined heart and renal failure.

Jie KE, van der Putten K, Wesseling S, Joles JA, Bergevoet MW, Pepers-de Kort F, Doevendans PA, Yasui Y, Liu Q, Verhaar MC, Gaillard CA, Braam B.

PLoS One. 2012;7(9):e41339. doi: 10.1371/journal.pone.0041339. Epub 2012 Sep 5.

2.

Short- and long-term effects of erythropoietin treatment on endothelial progenitor cell levels in patients with cardiorenal syndrome.

Jie KE, van der Putten K, Bergevoet MW, Doevendans PA, Gaillard CA, Braam B, Verhaar MC.

Heart. 2011 Jan;97(1):60-5. doi: 10.1136/hrt.2010.194654. Epub 2010 Nov 11.

3.

Erythropoietin treatment in patients with combined heart and renal failure: objectives and design of the EPOCARES study.

van der Putten K, Jie KE, Emans ME, Verhaar MC, Joles JA, Cramer MJ, Velthuis BK, Meiss L, Kraaijenhagen RJ, Doevendans PA, Braam B, Gaillard CA.

J Nephrol. 2010 Jul-Aug;23(4):363-8.

PMID:
20383871
4.

Erythropoietin resistance and survival in non-dialysis patients with stage 4-5 chronic kidney disease and heart disease.

Guerrero-Riscos MÁ, Montes-Delgado R, Seda-Guzmán M, Praena-Fernández JM.

Nefrologia. 2012 May 14;32(3):343-52. doi: 10.3265/Nefrologia.pre2012.Jan.11111. Epub 2012 Apr 17. English, Spanish.

5.

How the duration period of erythropoietin treatment influences the oxidative status of hemodialysis patients.

Dimitrijevic ZM, Cvetkovic TP, Djordjevic VM, Pavlovic DD, Stefanovic NZ, Stojanovic IR, Paunovic GJ, Velickovic-Radovanovic RM.

Int J Med Sci. 2012;9(9):808-15. doi: 10.7150/ijms.4910. Epub 2012 Oct 26.

6.

Determinants of red cell distribution width (RDW) in cardiorenal patients: RDW is not related to erythropoietin resistance.

Emans ME, van der Putten K, van Rooijen KL, Kraaijenhagen RJ, Swinkels D, van Solinge WW, Cramer MJ, Doevendans PA, Braam B, Gaillard CA.

J Card Fail. 2011 Aug;17(8):626-33. doi: 10.1016/j.cardfail.2011.04.009. Epub 2011 May 28.

7.
8.

Anemia correction by erythropoietin reduces BNP levels, hospitalization rate, and NYHA class in patients with cardio-renal anemia syndrome.

Palazzuoli A, Quatrini I, Calabrò A, Antonelli G, Caputo M, Campagna MS, Franci B, Nuti R.

Clin Exp Med. 2011 Mar;11(1):43-8. doi: 10.1007/s10238-010-0100-y. Epub 2010 May 29.

PMID:
20512394
9.

Oxidative stress: the effect of erythropoietin and the dialysis membrane.

Eiselt J, Racek J, Opatrný K Jr.

Int J Artif Organs. 2000 Jan;23(1):33-40.

PMID:
12118835
10.

Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.

Pérez-Oliva JF, Casanova-González M, García-García I, Porrero-Martín PJ, Valenzuela-Silva CM, Hernández-Montero T, Lagarde-Ampudia M, Casanova-Kutsareva Y, Avila-Albuerne Y, Vargas-Batista A, Bobillo-López H, Herrera-Valdés R, López-Saura PA; Bioequivalence Study of Erythropoietin Group.

BMC Nephrol. 2005 May 23;6:5.

11.

[Cardiorenal anemia syndrome (review)].

Minasyan A.

Georgian Med News. 2012 Dec;(213):17-21. Review. Russian.

PMID:
23293227
13.

Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response.

Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, Essers U, Greil R, Grossi A, Jäger G, LeMevel A, Najman A, Silingardi V, Spriano M, van Hoof A, Ehmer B.

Blood. 1995 Dec 15;86(12):4446-53.

14.
15.

Erythrocyte PAF-acetylhydrolase activity in various stages of chronic kidney disease: effect of long-term therapy with erythropoietin.

Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepis AD.

Kidney Int. 2005 Jul;68(1):246-55.

PMID:
15954914
16.

[Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].

Canaud B, Polito-Bouloux C, Rivory JP, Donnadieu P, Taib J, Florence P, Mion C.

Nephrologie. 1990;11(1):5-10. French.

PMID:
2374643
17.

Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.

Attallah N, Osman-Malik Y, Frinak S, Besarab A.

Am J Kidney Dis. 2006 Apr;47(4):644-54.

PMID:
16564942
18.

Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.

Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabrò A, Campagna SM, Nuti R.

Am Heart J. 2006 Dec;152(6):1096.e9-15.

PMID:
17161060
19.
20.

Erythropoietin administration suppresses human monocyte function in vitro and during therapy-induced anemia in HCV patients.

Spaan M, Groothuismink ZM, Koning L, Roomer R, Janssen HL, De Knegt RJ, Boonstra A.

Antiviral Res. 2013 Jun;98(3):469-75. doi: 10.1016/j.antiviral.2013.04.003. Epub 2013 Apr 11.

PMID:
23583759
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk